Pfizer Sees Stagnant Sales Through To 2012

Pfizer's disappointing 2009 financial results are mainly due to declining sales of its mega-blockbuster Lipitor (atorvastatin) and poor returns in emerging markets. Although revenue recorded by the New York City-based drugmaker rose by 3.5% compared with the previous year, a significant proportion of this increase was due to Wyeth products acquired in October 2009. A day after the release of the financial results, BMI notes that Pfizer has announced a renewed push into high-growth territories.

To read the full article, please take a trial.